These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27436224)

  • 1. Biomarkers in Persistent AF and Heart Failure: Impact of Catheter Ablation Compared with Rate Control.
    Jones DG; Haldar SK; Donovan J; McDonagh TA; Sharma R; Hussain W; Markides V; Wong T
    Pacing Clin Electrophysiol; 2016 Sep; 39(9):926-34. PubMed ID: 27436224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natriuretic Propeptides as Markers of Atrial Fibrillation Burden and Recurrence (from the AMIO-CAT Trial).
    Darkner S; Goetze JP; Chen X; Henningsen K; Pehrson S; Svendsen JH
    Am J Cardiol; 2017 Oct; 120(8):1309-1315. PubMed ID: 28865890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent effect of atrial fibrillation on natriuretic peptide release.
    Sramko M; Wichterle D; Melenovsky V; Franekova J; Clemens M; Fukunaga M; Kautzner J
    Clin Res Cardiol; 2019 Feb; 108(2):142-149. PubMed ID: 30051184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease in B-Type Natriuretic Peptide Levels and Successful Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure.
    Yanagisawa S; Inden Y; Kato H; Fujii A; Mizutani Y; Ito T; Kamikubo Y; Kanzaki Y; Hirai M; Murohara T
    Pacing Clin Electrophysiol; 2016 Mar; 39(3):225-34. PubMed ID: 26596862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of NT-proANP and NT-proBNP in patients with atrial fibrillation: Association with atrial fibrillation progression phenotypes.
    Büttner P; Schumacher K; Dinov B; Zeynalova S; Sommer P; Bollmann A; Husser D; Hindricks G; Kornej J
    Heart Rhythm; 2018 Aug; 15(8):1132-1137. PubMed ID: 29604419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-Term Influence of Radiofrequency Ablation on NT-proBNP, MR-proANP, Copeptin, and MR-proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF Study.
    Charitakis E; Walfridsson H; Alehagen U
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
    Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
    Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sinus rhythm restoration after electrical cardioversion on apelin and brain natriuretic Peptide prohormone levels in patients with persistent atrial fibrillation.
    Kallergis EM; Manios EG; Kanoupakis EM; Mavrakis HE; Goudis CA; Maliaraki NE; Saloustros IG; Milathianaki ME; Chlouverakis GI; Vardas PE
    Am J Cardiol; 2010 Jan; 105(1):90-4. PubMed ID: 20102897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial).
    Hunter RJ; Berriman TJ; Diab I; Kamdar R; Richmond L; Baker V; Goromonzi F; Sawhney V; Duncan E; Page SP; Ullah W; Unsworth B; Mayet J; Dhinoja M; Earley MJ; Sporton S; Schilling RJ
    Circ Arrhythm Electrophysiol; 2014 Feb; 7(1):31-8. PubMed ID: 24382410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catheter Ablation Versus Best Medical Therapy in Patients With Persistent Atrial Fibrillation and Congestive Heart Failure: The Randomized AMICA Trial.
    Kuck KH; Merkely B; Zahn R; Arentz T; Seidl K; Schlüter M; Tilz RR; Piorkowski C; Gellér L; Kleemann T; Hindricks G
    Circ Arrhythm Electrophysiol; 2019 Dec; 12(12):e007731. PubMed ID: 31760819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure.
    Jones DG; Haldar SK; Hussain W; Sharma R; Francis DP; Rahman-Haley SL; McDonagh TA; Underwood SR; Markides V; Wong T
    J Am Coll Cardiol; 2013 May; 61(18):1894-903. PubMed ID: 23500267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catheter ablation versus medical rate control for persistent atrial fibrillation in patients with heart failure: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials.
    Zhu M; Zhou X; Cai H; Wang Z; Xu H; Chen S; Chen J; Xu X; Xu H; Mao W
    Medicine (Baltimore); 2016 Jul; 95(30):e4377. PubMed ID: 27472728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high BNP level predicts an improvement in exercise tolerance after a successful catheter ablation of persistent atrial fibrillation.
    Katsumata Y; Tamura Y; Kimura T; Kohsaka S; Sadahiro T; Nishiyama T; Aizawa Y; Azuma K; Fukuda K; Takatsuki S
    J Cardiovasc Electrophysiol; 2019 Nov; 30(11):2283-2290. PubMed ID: 31471993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure).
    Richards M; Di Somma S; Mueller C; Nowak R; Peacock WF; Ponikowski P; Mockel M; Hogan C; Wu AH; Clopton P; Filippatos GS; Anand I; Ng L; Daniels LB; Neath SX; Shah K; Christenson R; Hartmann O; Anker SD; Maisel A
    JACC Heart Fail; 2013 Jun; 1(3):192-9. PubMed ID: 24621869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Left Atrial Appendage Amputation on Natriuretic Peptides-A Randomized Controlled Trial.
    Grieshaber P; Arneth B; Steinsberger F; Niemann B; Oswald I; Renz H; Böning A
    Thorac Cardiovasc Surg; 2021 Mar; 69(2):117-123. PubMed ID: 30929250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Midregional N-Terminal Pro-Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treated With Catheter Ablation for Atrial Fibrillation: The Biorhythm Study.
    Badoz M; Serzian G; Favoulet B; Sellal JM; De Chillou C; Hammache N; Laurent G; Mebazaa A; Ecarnot F; Bardonnet K; Seronde MF; Schiele F; Meneveau N
    J Am Heart Assoc; 2021 Jul; 10(13):e020917. PubMed ID: 34187182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between alcohol consumption, cardiac biomarkers, left atrial size and re-ablation in patients with atrial fibrillation referred for catheter ablation.
    Barmano N; Charitakis E; Kronstrand R; Walfridsson U; Karlsson JE; Walfridsson H; Nystrom FH
    PLoS One; 2019; 14(4):e0215121. PubMed ID: 30970005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation.
    Falcone C; Buzzi MP; D'Angelo A; Schirinzi S; Falcone R; Rordorf R; Capettini AC; Landolina M; Storti C; Pelissero G
    Int J Immunopathol Pharmacol; 2010; 23(3):917-25. PubMed ID: 20943064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma NT-proANP in patients with persistent atrial fibrillation who underwent successful cardioversion.
    Bartkowiak R; Wozakowska-Kapłon B; Janiszewska G
    Kardiol Pol; 2010 Jan; 68(1):48-54. PubMed ID: 20131188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.